News

Cyclacel Pharmaceuticals Advances Research in Liver Cancer Treatment

Cyclacel Pharmaceuticals Advances Research in Liver Cancer Treatment

Cyclacel Pharmaceuticals Advances Research in Liver Cancer Treatment

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) is making significant strides in the field of oncology with its focus on developing innovative cancer treatments. One of the most exciting developments in their pipeline is plogosertib, a promising agent that has shown activity against fibrolamellar hepatocellular carcinoma (FLC), a rare and hard-to-treat subtype of liver cancer mostly affecting younger adults.

Understanding Fibrolamellar Carcinoma

Fibrolamellar carcinoma (FLC) is distinguished by its unique characteristics, particularly its occurrence in patients with no known risk factors for liver cancer. This cancer tends to be diagnosed at later stages due to the absence of early symptoms, which often leads to misdiagnosis with more common forms of liver cancer such as hepatocellular carcinoma (HCC).

Incidence and Challenges

According to estimates from relevant sources, FLC has an annual incidence of approximately 0.02 per 100,000 in the U.S. The prognosis remains poor, with a five-year survival rate hovering around 30%. This harsh reality underscores the critical need for effective systemic therapies, especially for patients with non-resectable forms of the disease, which do not respond well to conventional chemotherapy.

Advancements in Research

Recent research has illuminated the molecular underpinnings of FLC, particularly the role of the DNAJ-PKAc fusion oncoprotein that drives tumor progression. This has opened new avenues for targeted therapy, notably with plogosertib. Studies suggest that plogosertib selectively inhibits PLK1, a key protein that is crucial for the survival of cancer cells, resulting in significant tumor reduction while sparing normal liver cells.

Plogosertib's Mechanism of Action

Plogosertib works by inhibiting Polo-like kinase 1 (PLK1), essential for cell division. Cancer cells, particularly those harboring KRAS mutations or lacking functional p53, show heightened sensitivity to PLK1 loss, leading to inhibited growth and eventual cancer cell death. This selectivity for cancerous cells over normal cells makes plogosertib a potential groundbreaking therapy for treating FLC.

Clinical Development and Tolerability

The initial results from a Phase 1 clinical trial of plogosertib have shown that it is well-tolerated among patients. Importantly, no dose-limiting toxicities have been observed across multiple dosing schedules. Patients with various cancer types, including adenoid cystic and biliary tract cancers, have also experienced clinical benefits, adding to the potential for plogosertib in oncological therapies.

Cyclacel’s Commitment to Oncology

Cyclacel Pharmaceuticals is dedicated to transforming cancer treatment through research and innovation. With a robust pipeline focused on cell cycle and mitosis biology, the company aims to develop novel drug candidates that can address multiple oncology and hematology indications. This commitment is reflected in their strategy to enhance patient care through targeted therapies that base their efficacy on the unique molecular features of various cancers.

Future Implications for Patients

As research progresses, the hope is that therapies like plogosertib could provide new options for patients suffering from FLC and similar cancers. The focus on personalization of cancer treatment through targeted therapy represents a major shift in how oncologists approach treatment plans, providing hope for improved outcomes.

Frequently Asked Questions

What is fibrolamellar carcinoma?

Fibrolamellar carcinoma (FLC) is a rare liver cancer primarily affecting younger individuals, characterized by the absence of typical risk factors for liver malignancies.

How does plogosertib work?

Plogosertib is a selective inhibitor of Polo-like kinase 1 (PLK1), a protein that is crucial for cell division and survival in cancer cells, leading to cell death in those affected by FLC.

What is the significance of DNAJ-PKAc fusion in FLC?

The DNAJ-PKAc fusion oncoprotein enhances the sensitivity of FLC cells to PLK1 inhibitors like plogosertib, making it a potential target for effective treatment.

What are the clinical trial results for plogosertib?

Initial studies have indicated that plogosertib is well tolerated and shows clinical benefits in patients with various cancer types, including those suffering from fibrolamellar carcinoma.

Where can I find more information about Cyclacel?

For more details about Cyclacel Pharmaceuticals and their ongoing research, please visit their official website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 115

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
Caregiver Strategy Puts a Hard Truth on the Table Today

Updated Category News Views 57

Sixty-three million people carrying care responsibilities is not a side issue; it is a national load-bearing wall. The 2026 National Strategy to Support Family Caregivers arrives with that reality plainly in view, and frankly, it is overdue for the country to treat family care as core infrastructure rather than a private household problem somebody is expected to absorb...

Continue Reading
Mindstream’s Jordan AI Campus Faces Its First Real Test

Updated Category News Views 65

Jordan’s AI ambitions just got attached to a very large gas meter. Mindstream Energy has unveiled a plan for an AI-ready data-center campus at Al-Risha in Mafraq Governorate, built around dedicated natural-gas generation rather than a conventional dependence on the utility grid. The headline number is 400 megawatts of eventual capacity. The number that matters first is...

Continue Reading
DHC’s Ulta Rollout Gets a Useful Pricing Correction

Updated Category News Views 49

A face-wash price tag just became the most revealing part of DHC’s Ulta expansion. The company corrected an earlier announcement that had listed its new Deep Cleansing Face Wash at $31.50; the actual price is $19.00. That may sound like tiny housekeeping, and in the grand scheme it is, but consumer brands live or die on this kind of detail. A cleanser priced near $20...

Continue Reading
Zoomcar's November 23 Report Puts Execution on Trial

Updated Category News Views 130

A Date on the Board, Not a Verdict November 23 is when Zoomcar finally has to put some fresh numbers beside the story. The Bengaluru-based peer-to-peer car-sharing marketplace says it will release second-quarter fiscal 2027 financial and operating results that Monday, covering the quarter ended September 30, 2026. Management also plans a live webcast at 8:00 a.m. Eastern...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 141

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
Alphabet Lawsuit Puts Gemini Delays Under a Microscope

Updated Category News Views 173

July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 146

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 12

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
SM's PHP70 Billion Profit Shows a Balanced Growth Engine

Updated Category News Views 0

PHP70.2 billion in nine-month profit is not the sort of number that needs a brass band; it needs a closer look at the machinery underneath. SM Investments grew consolidated net income 9% from PHP64.4 billion a year earlier, while revenue rose a more modest 5% to PHP506.8 billion. That spread is encouraging, but it also tells investors not to lazily call this a one-speed...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Announced by Halper Sadeh LLC for Shareholders

Updated Category News Views 131

Halper Sadeh LLC Launches Investigative Inquiry Halper Sadeh LLC, a firm advocating for investor rights, has initiated an investigation into two companies: ODP Corporation (NASDAQ: ODP) and Metsera, Inc. (NASDAQ: MTSR). The focus of this inquiry is to examine potential breaches of fiduciary duties and violations of federal securities laws that impact shareholders. Details...

Continue Reading
Gran Tierra Energy Expands Offering with $150 Million Notes Sale

Updated Category News Views 205

Gran Tierra Energy’s Strategic Offering Announcement Gran Tierra Energy Inc. (NASDAQ: GTE) has made an important move in its corporate strategy by unveiling an additional offering of $150 million through its 9.500% Senior Secured Amortizing Notes due in 2029. This decision underscores the company’s dedication to improving its financial standing and further financing...

Continue Reading
Upstart Unveils T-Prime: A New Era for AI Lending

Updated Category News Views 124

Introducing Upstart's T-Prime Lending Program Upstart (NASDAQ: UPST), an innovative player in the artificial intelligence (AI) lending landscape, has recently taken a significant step forward with the launch of its T-Prime lending program. This exciting initiative enhances the Upstart Referral Network, enabling financial institutions such as banks and credit unions to...

Continue Reading
Oncotelic Showcases Innovations in Cancer Research at SITC

Updated Category News Views 180

Oncotelic's Recent Contributions to Cancer Research Oncotelic Therapeutics, Inc. has recently made significant strides in the field of oncology by presenting its research efforts at a notable conference. Leading the charge is Dr. Cynthia Lee, who serves as the Vice President of Research and Development. Her commitment to advancing cancer treatments has made a profound...

Continue Reading
Mammoth Energy Services Reports Q3 2024 Performance Highlights

Updated Category News Views 242

Mammoth Energy Services Reports Q3 2024 Performance Highlights Mammoth Energy Services, Inc. (NASDAQ: TUSK) recently shared its operational and financial results for the third quarter, revealing encouraging developments within its business sectors. Arty Straehla, the Chief Executive Officer, expressed optimism about the future, highlighting a hopeful turnaround in their...

Continue Reading